CO2019010035A2 - Síntesis de inhibidor de mcl-1 - Google Patents

Síntesis de inhibidor de mcl-1

Info

Publication number
CO2019010035A2
CO2019010035A2 CONC2019/0010035A CO2019010035A CO2019010035A2 CO 2019010035 A2 CO2019010035 A2 CO 2019010035A2 CO 2019010035 A CO2019010035 A CO 2019010035A CO 2019010035 A2 CO2019010035 A2 CO 2019010035A2
Authority
CO
Colombia
Prior art keywords
synthesis
mcl
inhibitor
compound
intermediates
Prior art date
Application number
CONC2019/0010035A
Other languages
English (en)
Inventor
Craig Stewart
Simon Hardy
Andrew Stark
Alexander Hird
Qing Ye
Xiaolan Zheng
Cati Ferrar
Jan Koek
Debasis Hazra
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2019010035A2 publication Critical patent/CO2019010035A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/74—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/76—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Lubricants (AREA)

Abstract

Se dan a conocer productos intermedios y métodos de síntesis del compuesto 1. Compuesto 1
CONC2019/0010035A 2017-03-31 2019-09-16 Síntesis de inhibidor de mcl-1 CO2019010035A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479493P 2017-03-31 2017-03-31
PCT/EP2018/058056 WO2018178227A1 (en) 2017-03-31 2018-03-29 Synthesis of mcl-1 inhibitor

Publications (1)

Publication Number Publication Date
CO2019010035A2 true CO2019010035A2 (es) 2019-09-30

Family

ID=61827753

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0010035A CO2019010035A2 (es) 2017-03-31 2019-09-16 Síntesis de inhibidor de mcl-1

Country Status (17)

Country Link
US (1) US11149024B2 (es)
EP (1) EP3601230B1 (es)
JP (1) JP7032428B2 (es)
KR (1) KR102604876B1 (es)
CN (1) CN110536884B (es)
AR (1) AR111304A1 (es)
AU (1) AU2018244180B2 (es)
BR (1) BR112019019686A2 (es)
CA (1) CA3056712A1 (es)
CO (1) CO2019010035A2 (es)
EA (1) EA038226B1 (es)
ES (1) ES2909751T3 (es)
IL (1) IL269410B2 (es)
MX (1) MX2019011468A (es)
TW (1) TWI781996B (es)
WO (1) WO2018178227A1 (es)
ZA (1) ZA201905645B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI749404B (zh) * 2018-11-22 2021-12-11 大陸商蘇州亞盛藥業有限公司 作為mcl-1抑制劑的大環吲哚
US20220396587A1 (en) * 2019-01-23 2022-12-15 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrrazoles as mcl-1 inhibitors
MX2021015770A (es) 2019-06-21 2022-04-12 Janssen Pharmaceutica Nv Inhibidores macrociclicos de mcl-1.
MX2022000390A (es) 2019-07-09 2022-02-10 Janssen Pharmaceutica Nv Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
EP4061820A1 (en) 2019-11-21 2022-09-28 Janssen Pharmaceutica NV Macrocyclic sulfonyl derivatives as mcl-1 inhibitors
MX2022006179A (es) 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de indol como inhibidores de mcl-1.
CA3168355A1 (en) 2020-02-21 2021-08-26 Frederik Jan Rita Rombouts Macrocyclic indole derivatives as inhibitors of mcl-1
EP4157852A1 (en) 2020-05-29 2023-04-05 JANSSEN Pharmaceutica NV Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
BR112022025631A2 (pt) 2020-06-19 2023-01-17 Janssen Pharmaceutica Nv Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1
JP2023530985A (ja) 2020-06-19 2023-07-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の阻害剤としてのｎ結合大環状７－（ピラゾール－５－イル）－インドール誘導体
US20230250109A1 (en) 2020-07-08 2023-08-10 Janssen Pharmaceutica Nv Macrocyclic ether containing indole derivatives as inhibitors of mcl-1
WO2022032284A1 (en) * 2020-08-07 2022-02-10 Zeno Management, Inc. Macrocyclic compounds
AU2021403616A1 (en) 2020-12-17 2023-08-03 Janssen Pharmaceutica Nv Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
MX2023009475A (es) 2021-02-12 2023-08-22 Janssen Pharmaceutica Nv Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer.
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
KR20240019283A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항암제의 병용

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2915811A1 (en) * 2014-03-04 2015-09-09 Centre Régional de Lutte contre le Cancer - Centre François Baclesse MCL-1 modulating compounds for cancer treatment
US9949965B2 (en) * 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
CO2018008759A2 (es) * 2016-04-22 2018-09-20 Astrazeneca Ab Inhibidores de mcl-1 y métodos de uso de los mismos
CN106478606B (zh) * 2016-09-21 2019-05-10 沈阳药科大学 N-取代吲哚类衍生物及其应用

Also Published As

Publication number Publication date
US20210122735A1 (en) 2021-04-29
EA038226B1 (ru) 2021-07-27
ZA201905645B (en) 2020-05-27
EP3601230B1 (en) 2022-01-26
TW201902868A (zh) 2019-01-16
KR20190136039A (ko) 2019-12-09
AU2018244180B2 (en) 2021-03-04
MX2019011468A (es) 2019-11-01
WO2018178227A1 (en) 2018-10-04
CA3056712A1 (en) 2018-10-04
US11149024B2 (en) 2021-10-19
ES2909751T3 (es) 2022-05-10
IL269410B (en) 2022-11-01
CN110536884A (zh) 2019-12-03
AU2018244180A1 (en) 2019-11-07
IL269410A (en) 2019-11-28
JP7032428B2 (ja) 2022-03-08
KR102604876B1 (ko) 2023-11-22
JP2020515557A (ja) 2020-05-28
CN110536884B (zh) 2023-05-02
EP3601230A1 (en) 2020-02-05
AR111304A1 (es) 2019-06-26
EA201992235A1 (ru) 2020-02-10
BR112019019686A2 (pt) 2020-04-14
IL269410B2 (en) 2023-03-01
TWI781996B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
CO2019010035A2 (es) Síntesis de inhibidor de mcl-1
DK3880670T3 (da) Forbedret syntese af nøglemellemprodukt af kras-g12c-hæmmerforbindelse
CL2019000992A1 (es) Conjugados de pirrolobenzodiazepina.
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
MD3645518T2 (ro) Sinteză de mercabil omecamtiv
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201892430A1 (ru) Синтез индазолов
DK3746424T3 (da) Erbb/btk-inhibitorer
EA201791684A1 (ru) Селективные ингибиторы bace1
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
ECSDI17044309S (es) Mandolina
MA54901A (fr) Inhibiteur de 15-pgdh
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
ECSDI17052034S (es) Cantimplora
ECSDI18067754S (es) Prensa de ajo
ECSDI17072109S (es) Recipiente contenedor (iii)
EA201892051A1 (ru) Фармацевтические композиции для лечения злокачественного новообразования
EA202091259A1 (ru) Способ получения опикапона и его интермедиатов
CL2017000645A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
ECSDI18002267S (es) Mandolina
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
IT201900025348A1 (it) Procedimento per la sintesi di melfalan
CL2019000807S1 (es) Cabezal de cepillo de dientes.
CL2019000806S1 (es) Cabezal de cepillo de dientes.